90Y-DOTA-3-tyr-Octreotide

DRUG2 trials

Sponsors

Sue O'Dorisio, David Bushnell

Conditions

MedulloblastomaMeningiomaNeuroblastomaNeuroendocrine Tumor Gastrointestinal, Hormone-SecretingNeuroendocrine Tumor, MalignantNeuroendrocrine Tumors

Early Phase 1

Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors

Active, not recruitingNCT03044977

David BushnellNeuroendocrine Tumor Gastrointestinal, Hormone-Secreting, Neuroendocrine Tumor, Malignant

Start: 2017-05-07End: 2027-12-31Target: 20Updated: 2023-08-16

Phase 2

Dosimetry Guided PRRT With 90Y-DOTATOC

WithdrawnNCT03013387

Sue O'DorisioMedulloblastoma, Meningioma, Neuroblastoma +1

Start: 2017-01-31End: 2019-10-31Updated: 2017-08-25